Pharmaceutical-Grade Protein Hydrolysates Market Size - By Protein Source, By Manufacturing Process, By Application, By End Use Industry, Growth Forecast, 2025 - 2034

Pharmaceutical-Grade Protein Hydrolysates Market size

The global pharmaceutical-grade protein hydrolysates market size was estimated at USD 2.4 billion in 2024. The market is expected to grow from USD 2.5 billion in 2025 to USD 4.4 billion in 2034, at a CAGR of 6.3% according to latest report published by Global Market Insights Inc.

• The fast, ever-increasing growth of the pharma-grade protein hydrolysates market is due to rise in demand for tailored nutritional and therapeutic products. Protein hydrolysates are proteins that have been broken down into smaller peptides or amino acids by enzymatic or acid processing, improving their digestibility and bioavailability. Their importance in the pharmaceutical industry is direct as they are core ingredients used in medical nutrition, functional foods, and dietary supplements addressing malnutrition, disorders related to the gastrointestinal tract and immune deficiencies.
   
• Pharmaceutical-grade protein hydrolysates have several advantages. They possess the best levels of purity and safety, and efficacy, and hence can be used for sensitive populations such as infants, the elderly, and patients with compromised factors of health. Moreover, these hydrolysates aid in muscle growth, wound healing, and immune functions, which is part of their therapeutic attributes.
   
• The market is well distributed in different sectors regarding their applications. In medical nutrition, they are used in special formulas for malnourished patients and patients affected by chronic illnesses. In pharmaceuticals, they are integrated into drug delivery systems as well as into active ingredients in formulations meant to manage specific health conditions. The sports nutrition segment also enjoys such hydrolysates since they support muscle synthesis and recovery.
   
• North America is the largest market for pharmaceutical-grade protein hydrolysates due to advancement in technology and research facilities in U.S. & Canada.
   
• Asia Pacific is the fastest growing region for pharmaceutical-grade protein hydrolysates market, due to increasing need from medical industry, also the region can enhance its performance in this market in the coming years.
   

Pharmaceutical-Grade Protein Hydrolysates Market Trends

• The pharmaceutical-grade protein hydrolysates industry is characterized by changes due to technological developments, product innovations and regulatory considerations. Recent trends show an increasing emphasis on advanced processing methods for protein hydrolysates that potentially enhance bioavailability, purity, and functionalities. Enzymatic hydrolysis is emerging as one of the best processing techniques with specificity, efficiency, and targeted health benefits in the production of proprietary bioactive peptides. It has created a platform with respect to extraction and purification technologies that help manufacturers produce superior products to meet the stringent quality of pharmaceutical standards.
   
• Another trend includes product innovation where firms are venting efforts in producing specialized hydrolysates for defined therapeutic and nutritional applications. Some current trends in product development are hypoallergenic formulations for infants and elderly patients, as well as hydrolysates fortified with bioactive peptides to assist with immune health. Hydrolysate products are beginning to add novel ingredients such as plant or alternative proteins in response to consumer requests for plant-derived and sustainable options.
   
• Pharmaceutical-grade protein hydrolysates are undergoing inspecting in regulatory frameworks to ensure safety, efficacy, and quality of the products. Regulatory authorities are defining additional guidelines regarding manufacturing practices concerning labeling and clinical validation of such products. Companies are putting into place compliance infrastructure through good manufacturing practices (GMP) and obtaining needed approvals for the applications of pharmaceutical and medical nutrition. This additional layer of regulatory scrutiny increases product credibility and trust among consumers.
   

Pharmaceutical-Grade Protein Hydrolysates Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on protein sources, the pharmaceutical-grade protein hydrolysates market is segmented into milk-derived protein hydrolysates, plant-derived protein hydrolysates, animal-derived protein hydrolysates, fish/marine protein hydrolysates, other sources hydrolysates.
 

• Milk-derived hydrolysates dominate because of their high bioavailability, safety, and clinical nutrition effectiveness. They are widely used in infant formulas, medical foods, and dietary products. Their growing demand due to being lactose-free and hypoallergenic increases their popularity. Developments in enzymatic hydrolysis techniques ensure these proteins are of high quality and easily digestible.
   
• Plant-derived hydrolysates show rapid growth with a CAGR of 9.8% by 2034 being pushed primarily by the sustainability trend and clean-label preferences, with an effort in combating the lactose allergies. The major plant sources comprise soy protein isolates, pea protein and others. Enzymatic hydrolysis of these plant proteins improves some functional limitations including poor solubility at acidic pH enabling application in various fortified beverages and clinical nutrition products.
   
• Animal hydrolysates accounted for 14% of the market share in 2024, covering different sources of protein derived from poultry, pork, and others. These hydrolysates have amino acid profiles and high digestibility, and they are useful in clinical nutrition and specialized medical foods.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on manufacturing process, the pharmaceutical-grade protein hydrolysates market is segmented into enzymatic hydrolysis, chemical hydrolysis, microbial fermentation, and hybrid/sequential processes.
 

• Enzymatic hydrolysis leads the way in the manufacturing processes with 73% share in 2024 because of its preciseness, safety and the ability to generate high-purity products with minimal by-products. Pharmaceutical manufacturers prefer this process since it meets the rigorous pharmaceutical standards and regulations compliance.
   
• Previously, chemical hydrolysis was the main route in which products were made but now enzymatic hydrolysis takes over this segment because of adverse effects left by residual chemicals and possible impurities that compromise safety and efficacy.
   
• Microbial fermentation is becoming a green and sustainable alternative because it is more specific and requires lower processing conditions which appeal to green consumers and manufacturers. Emerging innovations are hybrid or sequential processes, where combined enzymatic and microbial methods promise maximized yield, purity, and functional properties of the hydrolysates.
   

Based on application, the pharmaceutical-grade protein hydrolysates market is segmented into clinical/enteral nutrition, medical foods/FSMP, therapeutic/pharma, infant formula, parenteral nutrition, and sports nutrition.
 

• Clinical and enteral nutrition products are in increasing demand due to the rise in chronic diseases, malnutrition, and the world population that is growing older. Among all available options, the protein hydrolysates graded for pharmaceutical applications are the most favored since they are easy to digest and are highly bioavailable, hence ideal for patients in compromised digestion or absorption.
   
• The field of medical foods and food for special medical purposes is booming by the day as people gain awareness of issues regarding personalized nutrition for specific health conditions. Pharmaceutical-grade protein hydrolysates are used in formulating products for conditions such as phenylketonuria, food allergies, and metabolic disorders.
   
• Protein hydrolysates are incorporated into therapeutics or pharmaceutical formulations, supplements, and functional therapies, thus developing a greater market. Growing R&D and breakthroughs with respect to enzymatic processing open the genesis of highly specific, bioactive hydrolysates. Compliance about regulation and clinical validation would be a key to widening the market within this segment.
   
• The infant formula segment is likely to see steady growth, driven by increased customers' awareness of infant nutrition. Pharmaceutical-grade protein hydrolysates are used to produce hypoallergenic formulas for infants at risk of allergies or with sensitive digestion.
   

Based on end use industry, the pharmaceutical-grade protein hydrolysates market is segmented into medical nutrition manufacturers, pharmaceutical companies, infant formula manufacturers, and nutraceutical companies.
 

• Medical nutrition manufacturers represent 40% of the market share in 2024 and include the companies involved in clinical nutrition, enteral nutrition, oral nutritional supplements and medical foods. These manufacturers offer products for health care settings, provide home health care and sell directly to consumers. Products are oriented toward malnutrition and illness-specific nutritional needs and are designed for recovery support. 
   
• Infant formula manufacturers represent 22% of market share in 2024, producing both standard infant formulas and specialized formulas including hypoallergenic formulas for the management of milk protein allergies.
   
• Nutraceutical companies occupying an 8% market share in 2024 which are engaged in the development of dietary supplements, functional foods, and wellness products that incorporate protein hydrolysates with bioactive peptide ingredients. Applications include health and wellness benefits such as support of cardiovascular health, antioxidant protection, immune support, healthy aging, and sports performance.
   

Looking for region specific data?

Download Free PDF

North America accounted for the largest share of the pharmaceutical-grade protein hydrolysates market with 36.9% of the market share in 2024 and 5.5% CAGR through 2034 with US occupying the market of USD 704 million in 2024.
 

• The market in North America is being driven by the elderly, rising number of chronic diseases, and personalized medicine. The increasing demand for clinical nutrition and medical foods is fueling growth. Strict regulations and technological enhancements in processing contribute to the delivery of high-quality products. The pharmaceutical and nutraceutical industries flourish in this region, coupled with high health care expenditure in support of innovation and market growth, making North America an important player in global market growth.
   

Europe pharmaceutical-grade protein hydrolysates market accounted for USD 715 million in 2024 and is anticipated to show steady growth over the forecast period.
 

• A well-established health care system, increasing awareness about specialized nutrition and stringent safety standards are the key driving factors for the growth of the pharmaceutical-grade protein hydrolysate market in Europe. Malnutrition, allergies, and chronic diseases are prevalent, thereby driving demand for tailored nutritional solutions. Regulatory frameworks, including the EU with strict quality controls, make Europe a mature and competitive market.
   

The Asia Pacific pharmaceutical-grade protein hydrolysates market is anticipated to grow at the CAGR of 9.5% during the analysis timeframe till 2034.
 

• Increasing healthcare awareness, a growing middle-class population, and rising disposable incomes, are some reasons for the rapid growth in Asia Pacific. In countries like China and India there is a high demand for infant formulas, clinical nutrition, and nutraceuticals containing protein hydrolysates. Local manufacturing capabilities and investment in healthcare infrastructure place further market support. With the region's thrust for innovation at an affordable price, the expected growth from such will be substantial in the upcoming years, making it a market with good returns.
   

Latin America pharmaceutical-grade protein hydrolysates market accounted for 5% market share in 2024 and is anticipated to show steady growth over the forecast period.
 

• The market for pharmaceutical-grade protein hydrolysates in Latin America is driven by increasing awareness about the nutrition-health interface, rising chronic disease burden, and improving healthcare infrastructure. The demand for specialized clinical nutrition and infant formulas is steadily increasing. Manufacturers are improving the quality of products by conforming to the requirements of international standards. Economic growth with the increasing number of aging populations is another factor for the common acceptance of protein hydrolysates and is giving new opportunities for the players in the market.  
   

Middle East & Africa pharmaceutical-grade protein hydrolysates market accounted for 4% market share in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The Middle East & Africa is experiencing emerging growth in pharmaceutical-grade hydrolysates, primarily driven by increasing healthcare investments and rising malnutrition and chronic disease burden. The increasing awareness regarding specialized nutrition products, coupled with urbanization and economic development, contributes to the overall growth of the market. Both local and international companies are emphasizing improving the accessibility and affordability of their products. Regulatory improvements and increasing healthcare infrastructure are expected to support the growth of the market in this region over the next few years.
   

Pharmaceutical-Grade Protein Hydrolysates Market Share

The top 5 companies in the pharmaceutical-grade protein hydrolysates industry include Fonterra NZMP, Arla Foods Ingredients Group, FrieslandCampina Ingredients, Glanbia plc, Kerry Group plc. These are prominent companies operating in their respective regions covering 44.7% market share. These companies hold strong positions globally due to their experience in pharmaceutical-grade protein hydrolysates market. Their diverse product portfolios, backed by robust production capabilities and distribution networks, enable them to meet the rising demand across various regions.
 

• Fonterra NZMP is well-established as one of the monumental leaders in dairy ingredients. Fonterra NZMP is specifically recognized for its protein hydrolysates of high quality. By virtue of its extensive R&D, robust supply chain, and commitment to quality, it stands to benefit from a competitive advantage. NZMP uses its considerable knowledge and innovative approach to dairy in meeting stringent standards laid for the pharmaceutical field so that it can expand its capability into the health-oriented market.
   
• Arla Foods Ingredients has an eminent reputation in providing innovative dairy solutions inclusive of pharmaceutical-grade protein hydrolysates. Their emphasis on research and development along with sophisticated manufacturing processes that ensure high purity and bioavailability does certainly add to the strength of Arla in the prevailing market scenario. With emphasis on health and wellness trends, their competitive position is further enhanced.
   
• FrieslandCampina Ingredients is another player in dairy-based ingredients with pharmaceutical-grade protein hydrolysates that have high bioactivity. They innovate technology whilst assuring quality for efficacy and safety of the product. Their product customization also benefits from a comprehensive dairy network and R&D setup.
   
• Glanbia specializes in functional and nutritional ingredients, including pharmaceutical-grade protein hydrolysates. It is with a focus on strong R&D activities and innovative products that Glanbia supports the making of high-quality bioavailable hydrolysates. It increases competitiveness that Glanbia looks to safety and regulatory compliance in each of their customer-specific solutions.
   
• Kerry is a strong global player of taste and nutrition solutions, one of which is pharmaceutical-grade protein hydrolysates. The continued investment and technical know-how allow the company to develop high-purity functional ingredients. Kerry's competitive strength is based on global presence, customer orientation, and emphasis on health and wellness trends.
   

Pharmaceutical-Grade Protein Hydrolysates Market Companies

Major players operating in the pharmaceutical-grade protein hydrolysates industry include:

• Abbott Laboratories
• AMCO Proteins
• Arla Foods Ingredients Group
• Fonterra NZMP
• FrieslandCampina Ingredients
• Glanbia plc
• Hilmar Cheese Company, Inc.
• Hofseth BioCare ASA
• Ingredia SA
• Kerry Group plc
• NINGBO INNO PHARMCHEM CO., LTD
   

Pharmaceutical-Grade Protein Hydrolysates Industry News

• In April 2025, FrieslandCampina Ingredients released its new performance and active nutrition ingredient called Nutri Whey ProHeat. The heat-stable whey protein is designed to meet the needs of performance and active nutrition products. This is not a highly specific antimicrobial hydrolysate product, but its novelty in protein processing (especially hydrolysis/heat-stability) is an indicator of a rising ability to customize peptide/protein systems, which are needed to develop antimicrobial-functioning hydrolysates.
   
• In November 2024, Arla Foods Ingredients launched Lacprodan DI-3092, a hydrolyzed whey protein for medical nutrition. It improves digestibility and absorption of amino acids, both of which have posed key challenges in medical nutrition applications.
   
• In May 2024, FrieslandCampina Ingredients launched its new concept, Biotis DHA Flex Powders and Biotis Fermentis, to adult nutrition with algae-based and fermented peptides+ prebiotics systems, at Vitafoods Europe. This trend has indicated growing interest in multifunctional peptide solutions (antimicrobial potential) and growing versatility of hydrolysate use in non-nutritional uses.   
   

This pharmaceutical-grade protein hydrolysates market research report includes in-depth coverage of the industry, with estimates & forecasts in terms of revenue (USD Million) and volume (Kilo Tons) from 2025 to 2034, for the following segments:

Click here to Buy Section of this Report

Market, By Protein Source

• Milk-derived protein hydrolysates
  • Whey protein hydrolysates
  • Casein hydrolysates
• Plant-derived protein hydrolysates
  • Soy protein hydrolysates
  • Pea protein hydrolysates
  • Others
• Animal-derived protein hydrolysates
  • Egg protein hydrolysates
  • Collagen/gelatin hydrolysates
• Fish/marine protein hydrolysates
• Other sources hydrolysates

Market, By Manufacturing Process

• Enzymatic hydrolysis
• Chemical hydrolysis
• Microbial fermentation
• Hybrid/sequential processes

Market, By Application

• Clinical/enteral nutrition
  • Polymeric formulations
  • Oligomeric/peptide-based formulations
  • Tube feeding applications
  • Oral nutritional supplements
  • Critical care & ICU nutrition
• Medical foods/FSMP
  • PKU & metabolic disorder formulations
  • Renal disease formulations
  • Hepatic disease formulations
  • Cystic fibrosis nutrition
• Therapeutic/pharmaceutical applications
  • Ace inhibition peptides
  • Antioxidant bioactive peptides
  • Immunomodulatory applications
  • Wound healing formulations
  • Drug delivery systems
• Infant formula
  • Partially hydrolyzed formulas (DH 10–30%)
  • Extensively hydrolyzed formulas (DH30–60%)
  • Amino acid-based formulas (DH >80%)
  • Hypoallergenic formulations
• Parenteral nutrition
  • Amino acid solutions
  • Dipeptide formulations (alanyl-glutamine)
  • Total parenteral nutrition (TPN)
  • Peripheral parenteral nutrition (PPN)
• Sports nutrition
  • Rapid absorption formulations
  • Muscle recovery applications
  • Performance enhancement products

Market, By End Use Industry

•  Medical nutrition manufacturers
• Pharmaceutical companies
• Infant formula manufacturers
• Nutraceutical companies

The above information is provided for the following regions and countries:

• North America  
  • U.S.
  • Canada
• Europe  
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific  
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America  
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa  
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa